Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Crown Crafts Announces Financial Results for First Quarter Fiscal 2026
-
Calian Reports Results for the Third Quarter
-
Form 8.3 - Tritax Big Box Reit Plc
-
Form 8.3 - Life Science REIT Plc
-
Form 8.5 (EPT/RI) - Inspired Plc
-
Guardian Capital Announces Fund Merger
-
KP Tissue declares a Quarterly Dividend of $0.18 per Common Share
-
KP Tissue Releases Second Quarter 2025 Financial Results
-
Marex Group plc announces second quarter 2025 results
-
Bitcoin Swift Presale Reaches Stage 4 With $580K+ in Volume and Over 2,100 Buyers Ahead of September 18 Deadline
-
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement
-
Inotiv, Inc. to Participate in Three Investor Conferences in September 2025
-
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
-
American Shared Hospital Services Reports Second Quarter 2025 Financial Results
-
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
-
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results
-
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
-
Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance
-
Lantronix to Report Fiscal 2025 Fourth Quarter Results on Aug. 27, 2025
-
BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series
-
Greenbacker sells 51 MW distributed solar portfolio, advancing strategic focus on scaled clean energy projects
-
Beamr in Q2-2025: Demonstrating the Validation of its Solution for the Autonomous Vehicle Market
-
Oroco Receives Positive Resolution from Mexico’s Environment Ministry
-
Mesa Air Group Reports Third Quarter Fiscal 2025 Results and Provides Update on Proposed Merger with Republic Airways Holdings Inc.
-
OMNI-LITE INDUSTRIES REPORTS SECOND QUARTER FISCAL 2025 RESULTS CONFERENCE CALL FOR INVESTORS AUGUST 14, 2025, AT 4:00 PM EDT
-
Vireo Growth Inc. Announces Second Quarter 2025 Results
-
Plug to Participate in the Canaccord Growth Conference
-
TeraWulf Reschedules Second Quarter 2025 Investor Conference Call to Thursday, August 14, 2025
-
PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update
-
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
-
Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)
-
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
-
Tilray Medical Forms Strategic Partnership in Italy to Broaden Access to Medical Cannabis Extracts
-
Form 8.3 - Empiric Student Property Plc
-
Form 8.5 (EPT/RI) - H&T Group Plc
-
Immatics Announces Second Quarter 2025 Financial Results and Business Update
-
Blubird Launches $BLU Token to Power the Future of Real-World Asset Tokenization
-
Rego Payment Architectures, Inc. and Aambé Financial Announce Partnership to Expand Financial Inclusion Across Indian Country
-
Form 8.5 (EPT/RI) - Greencore Group Plc
-
YieldMax® ETFs Announces Distributions on PLTY, ULTY, MARO, LFGY, MRNY and Others
-
Form 8.5 (EPT/RI) - Epwin Group Plc
-
Correction: Form 8.3 - Tritax Big Box Reit Plc
-
Endeavour Silver Announces Q2 2025 Financial Results; Earnings Call at 10AM PDT (1PM EDT) Today
-
RentRedi Makes 2025 Inc. 5000 List for Second Consecutive Year
-
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results
-
Gildan and HanesBrands Agree to Combine To Create a Global Basic Apparel Leader
-
K92 Mining Strengthens Community Affairs and External Relations Leadership with Key Appointments
-
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates
-
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
-
Intention to utilise an over allotment facility
